A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer
| Autor: | Mingjun Jiang, Saichun Qi, Ya Mao |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Cancer Research medicine.medical_specialty Esophageal Neoplasms Paclitaxel medicine.medical_treatment Locally advanced Antibodies Monoclonal Humanized Toxicology Carboplatin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Nimotuzumab Pharmacology (medical) Aged Pharmacology business.industry Chemoradiotherapy Middle Aged Esophageal cancer medicine.disease Rash Neoadjuvant Therapy Progression-Free Survival Surgery Survival Rate Radiation therapy 030104 developmental biology Oncology Bone marrow suppression chemistry 030220 oncology & carcinogenesis Female medicine.symptom business medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 84:1115-1123 |
| ISSN: | 1432-0843 0344-5704 |
| Popis: | The aim of this study was to evaluate the safety and efficacy of combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer. Patients with clinically resectable, locally advanced esophageal cancer treated with neoadjuvant chemoradiotherapy plus nimotuzumab were eligible for study participation. Radiotherapy was administered in 1.8 Gy once daily for 5 days per week up to a total dose of 41.4 Gy. Weekly nimotuzumab (200 mg/week) was administered following paclitaxel and carboplatin on the same day for 5 weeks. The primary end-point was the pathological complete response (pCR) rate and the secondary end-point was the safety, progression-free survival (PFS) and overall survival (OS). A total of 64 patients with a median age of 58 years were enrolled in this study. pCR was observed in 51.6% patients. Grade 3 acute toxicities were observed in 6 patients (9.4%), shown as bone marrow suppression. 7 patients experienced grade 1 transient skin rash during nimotuzumab treatment. The median PFS time and OS time were 64.6 and 68.2 months. Combined nimotuzumab and neoadjuvant chemoradiotherapy for clinically resectable, locally advanced esophageal cancer showed a significant anticancer effect with tolerable toxicities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink